A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of ASM-024 Administered by Dry Powder Inhalation to Healthy Subjects and Subjects With Stable Moderate Asthma
Phase of Trial: Phase I/II
Latest Information Update: 16 Feb 2015
At a glance
- Drugs ASM 024 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Asmacure
- 08 Feb 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Jun 2014 Planned End Date changed from 1 May 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 02 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.